Is high-dose radioimmunotherapy needed in non-Hodgkin’s lymphoma?

[1] Goldenberg DM(2002)Targeted therapy of cancer with radiolabeled antibodies J Nucl Med 43 693-713

[2] Postema EJ(2001)Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma Eur J Nucl Med 28 1725-1735

[3] Boerman OC(1999)Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies Clin Cancer Res 5 3304-3314

[4] Oyen WJ(1998)Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody Cancer Biother Radiopharm 13 1-12

[5] Raemaekers JM(1997)Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies J Nucl Med 38 409-418

[6] Corstens FH(1993)Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support N Engl J Med 329 1219-1224

[7] Behr TM(1999)Hodgkin’s disease and transplantation: a room with a (nontransplanter’s) view Semin Oncol 26 67-73

[8] Wörmann B(2000)High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends Clin Breast Cancer 1 197-209

[9] Gramatzki M(1997)Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 Cancer Immunol Immunother 44 179-188

[10] Riggert J(1995)Treatment of non-Hodgkin’s lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody Cancer Res 55 5899-5907

[1] Goldenberg DM(2002)Targeted therapy of cancer with radiolabeled antibodies J Nucl Med 43 693-713

[2] Postema EJ(2001)Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma Eur J Nucl Med 28 1725-1735

[3] Boerman OC(1999)Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies Clin Cancer Res 5 3304-3314

[4] Oyen WJ(1998)Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody Cancer Biother Radiopharm 13 1-12

[5] Raemaekers JM(1997)Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies J Nucl Med 38 409-418

[6] Corstens FH(1993)Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support N Engl J Med 329 1219-1224

[7] Behr TM(1999)Hodgkin’s disease and transplantation: a room with a (nontransplanter’s) view Semin Oncol 26 67-73

[8] Wörmann B(2000)High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends Clin Breast Cancer 1 197-209

[9] Gramatzki M(1997)Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 Cancer Immunol Immunother 44 179-188

[10] Riggert J(1995)Treatment of non-Hodgkin’s lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody Cancer Res 55 5899-5907